<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02543255</url>
  </required_header>
  <id_info>
    <org_study_id>15-051</org_study_id>
    <nct_id>NCT02543255</nct_id>
  </id_info>
  <brief_title>Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)</brief_title>
  <acronym>ACDC-RP</acronym>
  <official_title>Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC-RP Trial): A Randomized, Open-label, Multi-centre Phase-2 Study Evaluating the Pathological Complete Response (pCR) Rate Following Neoadjuvant Therapy in Participants With High-risk Prostate Carcinoma for Whom Radical Prostatectomy is Indicated</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of chemotherapy with cabazitaxel in addition to abiraterone&#xD;
      acetate, prednisone, and leuprolide in neoadjuvant setting prior to radical prostatectomy in&#xD;
      patients with high-risk prostate carcinoma. Half of the participants will receive treatment&#xD;
      with abiraterone acetate, prednisone, leuprolide, and cabazitaxel, while the other half will&#xD;
      receive only abiraterone acetate, prednisone, and leuprolide.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response</measure>
    <time_frame>24 weeks from start of treatment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-operative PSA levels</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>The effect of neoadjuvant leuprolide, and abiraterone acetate and prednisone with and without cabazitaxel on pre-operative PSA will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean nadir PSA levels</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>The effect of neoadjuvant leuprolide, abiraterone acetate, and prednisone with and without cabazitaxel on mean nadir PSA levels will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving a PSA &lt; 0.2 ng/mL</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>The percentage of participants achieving a PSA &lt; 0.2 ng/mL following treatment with neoadjuvant leuprolide, abiraterone acetate, and prednisone with and without cabazitaxel will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving a 50 and 90% decrease in PSA levels</measure>
    <time_frame>up to 24 weeks of treatment</time_frame>
    <description>The percentage of participants achieving a 50 and 90% decrease in PSA levels following treatment with neoadjuvant leuprolide, abiraterone acetate, and prednisone with and without cabazitaxel will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of positive surgical margins</measure>
    <time_frame>up to 24 weeks of treatment</time_frame>
    <description>The rate of positive surgical margins following treatment with neoadjuvant leuprolide, abiraterone acetate, and prednisone with and without cabazitaxel will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of near-complete response (&lt;5 mm tumour)</measure>
    <time_frame>up to 24 weeks of treatment</time_frame>
    <description>The rate of near-complete response (&lt;5 mm tumour) following treatment with neoadjuvant leuprolide, abiraterone acetate, and prednisone with and without cabazitaxel will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of extracapsular extension</measure>
    <time_frame>up to 24 weeks of treatment</time_frame>
    <description>The rate of extracapsular extension following treatment with neoadjuvant leuprolide, abiraterone acetate, and prednisone with and without cabazitaxel will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of positive seminal vesicle involvement</measure>
    <time_frame>up to 24 weeks of treatment</time_frame>
    <description>The rate of positive seminal vesicle involvement following treatment with neoadjuvant leuprolide, abiraterone acetate, and prednisone with and without cabazitaxel will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of nodal involvement</measure>
    <time_frame>up to 24 weeks of treatment</time_frame>
    <description>The rate of nodal involvement following treatment with neoadjuvant leuprolide, abiraterone acetate, and prednisone with and without cabazitaxel will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour proliferation (Ki-67 index)</measure>
    <time_frame>up to 24 weeks of treatment</time_frame>
    <description>Tumour proliferation, indexed using Ki-67 immunohistochemistry, following treatment with neoadjuvant leuprolide, abiraterone acetate, and prednisone with and without cabazitaxel will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Androgen receptor expression</measure>
    <time_frame>up to 24 weeks of treatment</time_frame>
    <description>Androgen receptor expression will be evaluated using immunohistochemistry following treatment with neoadjuvant leuprolide, abiraterone acetate, and prednisone with and without cabazitaxel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to 24 weeks of treatment</time_frame>
    <description>Incidence of adverse events will be evaluated for the duration of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of adverse events</measure>
    <time_frame>Aup to 24 weeks of treatment</time_frame>
    <description>Severity of adverse events will be evaluated for the duration of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Androgen levels (if optional biopsy tissue is available)</measure>
    <time_frame>up to 24 weeks of treatment</time_frame>
    <description>If the participants agrees to optional pre-treatment biopsy, androgen levels will be compared between the pre-treatment tissue samples and prostatectomy tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genomic alterations between pre- and post-treatment tissue</measure>
    <time_frame>up to 24 weeks of treatment</time_frame>
    <description>If the participants agrees to optional pre-treatment biopsy, genomic alterations between the pre-treatment tissue samples and prostatectomy tissue will be evaluated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Abiraterone acetate + prednisone + leuprolide + cabazitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm will receive abiraterone acetate (1000 mg/day), prednisone (5 mg twice daily), leuprolide (22.5 mg every 3 months), and cabazitaxel (20 mg/m2, with 6 mg pegfilgrastim administered 24 h following cabazitaxel) prior to radical prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abiraterone acetate + prednisone + leuprolide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to this arm will receive abiraterone acetate (1000 mg/day) , prednisone (5 mg twice daily), and leuprolide (22.5 mg every 3 months) prior to radical prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone acetate with prednisone</intervention_name>
    <description>Abiraterone acetate will be administered orally as a tablet at 1000 mg/day with prednisone (5 mg oral tablet, twice daily) for 24 weeks.</description>
    <arm_group_label>Abiraterone acetate + prednisone + leuprolide</arm_group_label>
    <arm_group_label>Abiraterone acetate + prednisone + leuprolide + cabazitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide</intervention_name>
    <description>Leuprolide will be administered by subcutaneous injection at 22.5 mg dose every 12 weeks for 24 weeks.</description>
    <arm_group_label>Abiraterone acetate + prednisone + leuprolide</arm_group_label>
    <arm_group_label>Abiraterone acetate + prednisone + leuprolide + cabazitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel with peg-filgrastim</intervention_name>
    <description>Cabazitaxel will be administered in 6 cycles, with 20 mg/m2 per cycle and 3 weeks between cycles.</description>
    <arm_group_label>Abiraterone acetate + prednisone + leuprolide + cabazitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide informed consent;&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate without neuroendocrine&#xD;
             differentiation or small cell features with a minimum of 3 cores positive for tumour;&#xD;
&#xD;
          -  Tumour biopsy tissue accessible for downstream evaluation;&#xD;
&#xD;
          -  Must be candidates for radical prostatectomy and considered surgically resectable by&#xD;
             urologic evaluation;&#xD;
&#xD;
          -  High Risk D'Amico score defined as either PSA &gt; 20, Gleason score ≥ 8 as determined by&#xD;
             the local pathologist; or T2c-3 based on DRE, pathologic review +/- imaging;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1;&#xD;
&#xD;
          -  No evidence of metastatic disease or nodal disease as determined by radionuclide bone&#xD;
             scans and computed tomography (CT)/magnetic resonance imaging (MRI); non-pathological&#xD;
             lymph nodes must be less than 15 mm in the short (transverse) axis;&#xD;
&#xD;
          -  Able to swallow the study drug(s) as prescribed and comply with study requirements;&#xD;
&#xD;
          -  Required initial laboratory values:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1500/μL;&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL;&#xD;
&#xD;
          -  Hemoglobin ≥ 90 g/L;&#xD;
&#xD;
          -  Creatinine ≤ 175 μmol/L;&#xD;
&#xD;
          -  Bilirubin ≤ upper limit of institutional normal (ULN);&#xD;
&#xD;
          -  AST/ALT ≤ 1.5 × ULN.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received an investigational agent within 4 weeks prior to screening;&#xD;
&#xD;
          -  Stage T4 prostate cancer by clinical examination or radiologic evaluation;&#xD;
&#xD;
          -  Hypogonadism or severe androgen deficiency as defined by screening serum testosterone&#xD;
             below the normal range for the institution;&#xD;
&#xD;
          -  Prior androgen deprivation, chemotherapy, surgery, or radiation for prostate cancer;&#xD;
&#xD;
          -  Receiving concurrent androgens, estrogens, or progestational agents, or received any&#xD;
             of these agents within the 6 months prior to randomization;&#xD;
&#xD;
          -  History of another malignancy within the previous 5 years other than curatively&#xD;
             treated nonmelanomatous skin cancer and non-muscle invasive bladder cancer;&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, cardiovascular disease, unstable angina pectoris, cardiac arrhythmia that&#xD;
             is symptomatic or requires active therapy; deep venous thrombosis within 3 months&#xD;
             prior to randomization;&#xD;
&#xD;
          -  Previous use, or participation in a clinical trial, of an investigational agent that&#xD;
             blocks androgen synthesis (e.g., abiraterone acetate, TAK-700, TAK-683, TAK-448) or&#xD;
             targets the androgen receptor (e.g., enzalutamide, BMS 641988);&#xD;
&#xD;
          -  Liver injury or disease (e.g., viral hepatitis, liver failure Child-Pugh Class C).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil E Fleshner, MD, MPH, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony Joshua, BSc (Med), MBBS, PhD, FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Prostate Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network, Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 3, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

